Zevra: FDA Advisory Committee Votes Favorably on Arimoclomol for NPC Patients

Zevra Therapeutics said a Food and Drug Administration advisory committee voted favorably on Arimoclomol as a treatment for patients with Niemann-Pick Disease Type C.